Dear Customer,

COVID-19 (coronavirus) is top of mind for us at McKesson Life Sciences and it is a situation that we are closely monitoring. We understand the responsibility we have to providers, stakeholders and patients. We also take the health and welfare of our employees and our communities seriously. In addition to communicating with our associates, we are reaching out to you, our valued customer, regarding business-continuity and disaster-recovery plans. These plans are designed to minimize disruption while protecting our employees, customers and patients.

I want to assure you, in response to the evolving impact of COVID-19, we are reviewing our business continuity plans with special attention to the following key elements:

  • Resilience: maintaining critical business functions and supporting infrastructure to minimize the potential for interruption
  • Contingency: planning for potential disruptions and the unexpected, so we are better able to cope effectively with whatever crisis may arise; including any that may be unforeseen
  • Recovery: ensuring that, should we experience service interruption, we have made appropriate arrangements to resume normal business operations as quickly as practicable under the circumstances and to restore functionality starting with the most critical functions

We expect our day-to-day policies for business conduct, including travel, to evolve and will be largely based on governmental public health guidance. We will do our part to help mitigate the spread of COVID-19 while performing vital functions in the healthcare supply chain.

Based on the latest guidance from the international public health agencies and the U.S. Centers for Disease Control (CDC), we are updating our travel policy and restricting all non-essential travel to / from Europe and between European countries. This is in addition to the restriction on non-essential travel to / from China, South Korea, Italy and Iran that we announced last week.

In the U.S., based on the latest information from the CDC, we are restricting non-essential travel to / from areas that have sustained community transmission of the COVID-19 virus. This includes the San Francisco area (Solano, San Francisco and Santa Clara Counties), Washington (King and Snohomish counties), Illinois (Cook County), Oregon (Washington County) and New York (NYC and Westchester County). Additionally, we are cancelling large meetings in impacted communities.

The most up-to-date communications about our response to this virus are on the McKesson website, and we encourage you to visit this page for the latest information as we continue to monitor the situation.

Kind regards,

Shawn Seamans signature


Shawn Seamans

President, McKesson Life Sciences